论文部分内容阅读
目的探讨孟鲁司特钠治疗小儿过敏性紫癜(HSP)的临床疗效。方法 180例HSP患儿,随机分为治疗组和对照组,各90例。两组均应用抗组胺药物、维生素C、钙剂等常规治疗治疗,治疗组再加用孟鲁司特钠咀嚼片口服,观察比较两组患儿疗效。结果治疗组患儿总有效率为96.7%(87/90),高于对照组的82.2%(74/90),但总有效率比较差异无统计学意义(P>0.05);治疗组消化道出血、皮肤紫癜、关节肿痛消失时间与住院时间均优于对照组,两组比较差异均有统计学意义(P<0.05);两组患者治疗过程中均未出现明显不良反应,两组比较差异无统计学意义(P<0.05)。经过1年的随访,治疗组的复发率为3.3%,低于对照组的16.7%,差异有统计学意义(P>0.05)。结论孟鲁司特钠治疗小儿过敏性紫癜的疗效确切,能较快缓解症状、缩短病程,依从性好,未发现明显不良反应,值得临床推广使用。
Objective To investigate the clinical efficacy of montelukast sodium in the treatment of children with Henoch-Schonlein purpura (HSP). Methods 180 cases of HSP children were randomly divided into treatment group and control group, 90 cases each. Both groups were given antihistamines, vitamin C, calcium and other conventional treatment, the treatment group plus montelukast sodium chewable tablets orally, observed and compared the efficacy of two groups of children. Results The total effective rate in the treatment group was 96.7% (87/90), which was higher than that in the control group (82.2%, 74/90), but the total effective rate was not significantly different (P> 0.05) Bleeding, skin purpura, disappearance of joint swelling and hospitalization time were better than the control group, the difference between the two groups were statistically significant (P <0.05); two groups of patients with no significant adverse reactions during treatment, the two groups compared The difference was not statistically significant (P <0.05). After one year of follow-up, the recurrence rate of the treatment group was 3.3%, which was lower than that of the control group (16.7%), the difference was statistically significant (P> 0.05). Conclusion Montelukast sodium treatment of children with anaphylactoid purpura exact effect, can quickly relieve symptoms and shorten the course of the disease, compliance is good, no significant adverse reactions, it is worth promoting the use of the clinic.